Rocklatan header logo
MENU CLOSE
water drop image

For the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension

Proven superior to latanoprost in phase 3 trials1

Rocklatan® is the first QD fixed-dose combination of prostaglandin + ROCK inhibitor that provides patients with superior efficacy1


Superior efficacy. Optimal simplicity.1,2

Over 60% of Rocklatan® patients reached IOP reductions of 30% or more—nearly twice as many as latanoprost3


Resources created specifically for eye care providers like you

Become a

Access engaging content, educational resources, and Aerie research for glaucoma care and beyond.


IMPORTANT SAFETY INFORMATION

Contraindications

None.

Warnings and Precautions

  • Pigmentation changes
  • Eyelash changes
  • Intraocular inflammation
  • Macular edema
  • Herpetic keratitis
  • Bacterial keratitis
  • Contact lens wear

Adverse reactions

Rocklatan®: The most common ocular adverse reaction is conjunctival hyperemia (59%). Five percent of patients discontinued therapy due to conjunctival hyperemia. Other common ocular adverse reactions were: instillation site pain (20%), corneal verticillata (15%), and conjunctival hemorrhage (11%). Eye pruritus, visual acuity reduced, increased lacrimation, instillation site discomfort, and blurred vision were reported in 5-8% of patients.

Netarsudil 0.02%: Instillation site erythema, corneal staining, increased lacrimation and erythema of eyelid.

Latanoprost 0.005%: Foreign body sensation, punctate keratitis, burning and stinging, itching, increased pigmentation of the iris, excessive tearing, eyelid discomfort, dry eye, eye pain, eyelid margin crusting, erythema of the eyelid, upper respiratory tract infection/nasopharyngitis/influenza, photophobia, eyelid edema, myalgia/arthralgia/back pain, and rash/allergic reaction.

Please click here for full prescribing information for Rocklatan®.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

INDICATIONS AND USAGE

Rocklatan® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% is approved for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

DOSAGE AND ADMINISTRATION

The recommended dosage is one drop in the affected eye(s) once daily in the evening. If one dose is missed, treatment should continue with the next dose in the evening. The dosage of Rocklatan® should not exceed once daily. Rocklatan® may be used concomitantly with other topical ophthalmic drug products to lower IOP. If more than one topical ophthalmic drug is being used, the drugs should be administered at least five (5) minutes apart.


IMPORTANT SAFETY INFORMATION

Contraindications

None.

Warnings and Precautions

  • Pigmentation changes
  • Eyelash changes
  • Intraocular inflammation
  • Macular edema
  • Herpetic keratitis
  • Bacterial keratitis
  • Contact lens wear

Adverse reactions

Rocklatan®: The most common ocular adverse reaction is conjunctival hyperemia (59%). Five percent of patients discontinued therapy due to conjunctival hyperemia. Other common ocular adverse reactions were: instillation site pain (20%), corneal verticillata (15%), and conjunctival hemorrhage (11%). Eye pruritus, visual acuity reduced, increased lacrimation, instillation site discomfort, and blurred vision were reported in 5-8% of patients.

Netarsudil 0.02%: Instillation site erythema, corneal staining, increased lacrimation and erythema of eyelid.

Latanoprost 0.005%: Foreign body sensation, punctate keratitis, burning and stinging, itching, increased pigmentation of the iris, excessive tearing, eyelid discomfort, dry eye, eye pain, eyelid margin crusting, erythema of the eyelid, upper respiratory tract infection/nasopharyngitis/influenza, photophobia, eyelid edema, myalgia/arthralgia/back pain, and rash/allergic reaction.

Please click here for full prescribing information for Rocklatan®.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

INDICATIONS AND USAGE

Rocklatan® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% is approved for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

DOSAGE AND ADMINISTRATION

The recommended dosage is one drop in the affected eye(s) once daily in the evening. If one dose is missed, treatment should continue with the next dose in the evening. The dosage of Rocklatan® should not exceed once daily. Rocklatan® may be used concomitantly with other topical ophthalmic drug products to lower IOP. If more than one topical ophthalmic drug is being used, the drugs should be administered at least five (5) minutes apart.

References:

  1. Rocklatan® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% Prescribing Information, Aerie Pharmaceuticals, Inc., Irvine, Calif. 2019.
  2. Asrani S, McKee H, Scott B, et al. Pooled phase 3 efficacy analysis of a once-daily fixed-dose combination of netarsudil 0.02% and latanoprost 0.005% in ocular hypertension and open-angle glaucoma. Presented at the 13th Biennial Meeting of the European Glaucoma Society, March 2018.
  3. Data on file, Aerie Pharmaceuticals, Inc.
  4. Prum B Jr, Rosenberg L, Gedde S, et al. Primary Open-Angle Glaucoma Preferred Practice Pattern guidelines. Ophthalmology. 2016;123(1):P41-P111.